{"id":42469,"date":"2023-09-06T06:45:08","date_gmt":"2023-09-06T13:45:08","guid":{"rendered":"https:\/\/vermont.salk.edu\/?post_type=disclosure&p=42469"},"modified":"2024-02-19T21:09:26","modified_gmt":"2024-02-20T05:09:26","slug":"super-enhancer-super-charges-pancreatic-tumor-growth","status":"publish","type":"disclosure","link":"https:\/\/www.salk.edu\/de\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/","title":{"rendered":"\u201cSuper-enhancer\u201d super-charges pancreatic tumor growth"},"content":{"rendered":"

LA JOLLA\u2014Pancreatic cancers are among the most aggressive, deadly tumor types and, for years, researchers have struggled to develop effective drugs against the tumors. Now, Salk researchers have identified a new set of molecules that fuel the growth of tumors in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. \r\n<\/p>

\r\nThe new research, published in Nature Communications<\/a><\/em> on September 6, 2023, explains how certain gene mutations trigger out-of-control growth in pancreatic cancer by activating a \u201csuper-enhancer\u201d that turns on other genes. It also showed the effectiveness of a new drug that put the brakes on pancreatic cancer growth by blocking the effects of that super-enhancer. \r\n<\/p>

\r\n\u201cThis is the first time anyone has looked in such detail at the role of super-enhancers in pancreatic cancer,\u201d says senior author and Salk Professor Ronald Evans<\/a>, director of Salk\u2019s Gene Expression Laboratory. \u201cThe discovery of this super-enhancer gives us both basic insight into PDAC and a new way to think of therapies.\u201d\r\n<\/p>\r\n

\"From
From Left: Gabriela Estepa, Ronald Evans, Ruth Yu, Corina Antal, Annette Atkins, and Michael Downes.
Klicken Sie hier<\/a> f\u00fcr ein hochaufl\u00f6sendes Bild.
Kredit: Salk Institut<\/figcaption><\/figure>\r\n\r\n

Enhancers are regions of DNA that, when bound by proteins, boost the expression of genes. This results in higher levels of those genes\u2019 protein products. Super-enhancers are the most active type of enhancer, and they can be identified by their unique molecular tags. Because super-enhancers can simultaneously and powerfully activate many genes, they can rapidly change the state of a cell, switching on cellular programs to encourage rapid growth or change the cell\u2019s identity, for instance. \r\n<\/p>

\r\nIn the new work, Evans\u2019 team analyzed 16 different human pancreatic cancer cell lines and identified hundreds of different super-enhancers. They pinpointed one, associated with the gene hnRNPF, that was far more active in pancreatic cancer cells than healthy cells. Then, through a series of experiments, the group showed how hnRNPF sets off a cascade of events leading to an increase in the amounts of overall proteins cells were producing. \r\n<\/p>

\r\n\u201cIt\u2019s well-established that cancer cells upregulate protein production in order to fuel their rapid growth,\u201d says first author Corina Antal, an assistant professor of pharmacology at UC San Diego School of Medicine who led the work as a postdoctoral researcher in Evans\u2019 lab. \u201cWe have now identified how cells regulate this process at the super-enhancer level.\u201d \r\n<\/p>

\r\nThe researchers went on to demonstrate that, by deleting the super-enhancer or the hnRNPF gene in the cell lines, they could slow the growth of pancreatic cancer cells by more than 80 percent. \r\n<\/p>

\r\nThey also found that an experimental drug targeting Prmt1, one of the proteins impacted by hnRNPF activation, could stop the growth of isolated pancreatic tumors in the lab and the growth of pancreatic tumors in mice. \r\n<\/p>

\r\n\u201cWe were excited to find that there\u2019s not a lot of redundancy in this super-enhancer pathway, which means there might be multiple ways to impact it with therapeutics,\u201d says Michael Downes, a senior staff scientist at Salk. \u201cIf you disrupt this network at any point, you have the same effect on blocking cellular growth.\u201d\r\n<\/p>

\r\nAdditionally, the team discovered that Myc, a cancer-related gene that\u2019s mutated in many cancers, including pancreatic cancer, can activate the hnRNPF super-enhancer. Drugs effectively blocking Myc have been hard to develop, and the new results suggest a completely different way of stopping the effects of these Myc mutations\u2014by targeting the pathway turned on by the super-enhancer. \r\n<\/p>

\r\nFinally, the researchers tested cells from a patient with pancreatic cancer and found that the hnRNPF super-enhancer was active in these cells. \r\n<\/p>

\r\n\u201cThese results clearly demonstrate that this super-enhancer is relevant in humans and could even be used as a marker to monitor pancreatic cancer progression,\u201d says Evans, March of Dimes Chair in Molecular and Developmental Biology. \r\n<\/p>

\r\nMore work is needed to discover whether drugs targeting the super-enhancer or related molecules might be useful for treating pancreatic cancer in patients.\r\n<\/p>

\r\nOther authors of the paper are Tae Gyu Oh, Nasun Hah, Jan C. Lumibao, Morgan L. Truitt, Gabriela Estepa, Ester Banayo, Senada Bashi, Jolene K. Diedrich, Ruth T. Yu, Annette R. Atkins, and Dannielle D. Engle of Salk; Stefan Aigner, En-Ching Luo, Brian A. Yee, Herv\u00e9 Tiriac, Katherine L. Rothamel, Zhang Cheng, Henry Jiao, Allen Wang, Edgar Esparza, Jasmine R. Mueller, Andrew M. Lowy, and Gene W. Yeo of UC San Diego; Tania Campos, Nicole M. Sodir and Gerard I. Evan of The Francis Crick Institute; Elizabeth Lenkiewicz and Michael T. Barrett of Mayo Clinic; Ruben Munoz, Erkut Borazanci, Daniel Von Hoff and Haiyong Han of the Translational Genomics Research Institute; Cory R. Fraser of HonorHealth Research Institute; David Propper of Queen Mary University of London; and Christopher Liddle of the University of Sydney. \r\n <\/p>

\r\nThe work was supported by grants from the Damon Runyon Cancer Research Foundation (DRG-2244-16), the National Institutes of Health (5T32CA009370, HL088093, HG004659, HG009889, CA155620, P01 CA265762-01A1, P42ES010337, R01DK057978), the Lustgarten Foundation, the Don and Lorraine Freeberg Foundation, the David C. Copley Foundation, Cancer Research UK (A12077), a SU2C-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research Grant (SU2C-AACR-DT-20-16), a study-abroad graduate student fellowship from the Taiwanese government, the Alexandrina McAfee Foundation, the Lustgarten Foundation for Pancreatic Cancer Research (122215393-02), a Samuel Waxman Cancer Research Foundation Investigator Award, and a Merck-supported Stand Up To Cancer (SU2C) Catalyst research grant (IWOV-OGC-SCIENTISTS.FID144019). \r\n<\/p>","protected":false},"featured_media":0,"template":"","faculty":[91],"disease-research":[46,333,172,331],"class_list":["post-42469","disclosure","type-disclosure","status-publish","hentry","faculty-ronald-evans","disease-research-cancer-biology","disease-research-genetics","disease-research-pancreatic-cancer","disease-research-protein-interactions"],"acf":[],"yoast_head":"\n\u201cSuper-enhancer\u201d super-charges pancreatic tumor growth - Salk Institute for Biological Studies<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.salk.edu\/de\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u201cSuper-enhancer\u201d super-charges pancreatic tumor growth - Salk Institute for Biological Studies\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA\u2014Pancreatic cancers are among the most aggressive, deadly tumor types and, for years, researchers have struggled to develop effective drugs against the tumors. Now, Salk researchers have identified a new set of molecules that fuel the growth of tumors in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.salk.edu\/de\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/\" \/>\n<meta property=\"og:site_name\" content=\"Salk Institute for Biological Studies\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-20T05:09:26+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/08\/Evans-PR-20230815-551A8741-1800-458x305.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/super-enhancer-super-charges-pancreatic-tumor-growth\\\/\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/super-enhancer-super-charges-pancreatic-tumor-growth\\\/\",\"name\":\"\u201cSuper-enhancer\u201d super-charges pancreatic tumor growth - Salk Institute for Biological Studies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/super-enhancer-super-charges-pancreatic-tumor-growth\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/super-enhancer-super-charges-pancreatic-tumor-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/Evans-PR-20230815-551A8741-1800-458x305.jpg\",\"datePublished\":\"2023-09-06T13:45:08+00:00\",\"dateModified\":\"2024-02-20T05:09:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/super-enhancer-super-charges-pancreatic-tumor-growth\\\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/super-enhancer-super-charges-pancreatic-tumor-growth\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/super-enhancer-super-charges-pancreatic-tumor-growth\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/Evans-PR-20230815-551A8741-1800-458x305.jpg\",\"contentUrl\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/Evans-PR-20230815-551A8741-1800-458x305.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/super-enhancer-super-charges-pancreatic-tumor-growth\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.salk.edu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u201cSuper-enhancer\u201d super-charges pancreatic tumor growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"name\":\"Salk Institute for Biological Studies\",\"description\":\"The Power of Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.salk.edu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\",\"name\":\"Salk Institute for Biological Studies\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"contentUrl\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Salk Institute for Biological Studies\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u201cSuper-enhancer\u201d super-charges pancreatic tumor growth - Salk Institute for Biological Studies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.salk.edu\/de\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/","og_locale":"de_DE","og_type":"article","og_title":"\u201cSuper-enhancer\u201d super-charges pancreatic tumor growth - Salk Institute for Biological Studies","og_description":"LA JOLLA\u2014Pancreatic cancers are among the most aggressive, deadly tumor types and, for years, researchers have struggled to develop effective drugs against the tumors. Now, Salk researchers have identified a new set of molecules that fuel the growth of tumors in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.","og_url":"https:\/\/www.salk.edu\/de\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/","og_site_name":"Salk Institute for Biological Studies","article_modified_time":"2024-02-20T05:09:26+00:00","og_image":[{"url":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/08\/Evans-PR-20230815-551A8741-1800-458x305.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.salk.edu\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/","url":"https:\/\/www.salk.edu\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/","name":"\u201cSuper-enhancer\u201d super-charges pancreatic tumor growth - Salk Institute for Biological Studies","isPartOf":{"@id":"https:\/\/www.salk.edu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.salk.edu\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/#primaryimage"},"image":{"@id":"https:\/\/www.salk.edu\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/#primaryimage"},"thumbnailUrl":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/08\/Evans-PR-20230815-551A8741-1800-458x305.jpg","datePublished":"2023-09-06T13:45:08+00:00","dateModified":"2024-02-20T05:09:26+00:00","breadcrumb":{"@id":"https:\/\/www.salk.edu\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.salk.edu\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.salk.edu\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/#primaryimage","url":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/08\/Evans-PR-20230815-551A8741-1800-458x305.jpg","contentUrl":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/08\/Evans-PR-20230815-551A8741-1800-458x305.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.salk.edu\/news-release\/super-enhancer-super-charges-pancreatic-tumor-growth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.salk.edu\/"},{"@type":"ListItem","position":2,"name":"\u201cSuper-enhancer\u201d super-charges pancreatic tumor growth"}]},{"@type":"WebSite","@id":"https:\/\/www.salk.edu\/#website","url":"https:\/\/www.salk.edu\/","name":"Salk-Institut f\u00fcr biologische Studien","description":"Die Macht der Wissenschaft","publisher":{"@id":"https:\/\/www.salk.edu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.salk.edu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.salk.edu\/#organization","name":"Salk-Institut f\u00fcr biologische Studien","url":"https:\/\/www.salk.edu\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/","url":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","contentUrl":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","width":696,"height":696,"caption":"Salk Institute for Biological Studies"},"image":{"@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/"}}]}},"ACF":{"hero":false,"line_1":"\u201cSuper-enhancer\u201d super-charges pancreatic tumor growth","line_2":"Salk researchers identified new set of molecules that drive growth of human pancreatic cancer cell lines, potentially leading to new therapeutic targets","poster_quote":"","gallery":false,"paper_url":"https:\/\/www.nature.com\/articles\/s41467-023-40798-6","journal_title":"Nature Communications","paper_author_list":"Corina E. Antal, Tae Gyu Oh, Stefan Aigner, En-Ching Luo, Brian A. Yee, Tania Campos, Herv\u00e9 Tiriac, Katherine L. Rothamel, Zhang Cheng, Henry Jiao, Allen Wang, Nasun Hah, Elizabeth Lenkiewicz, Jan C. Lumibao, Morgan L. Truitt, Gabriela Estepa, Ester Banayo, Senada Bashi, Edgar Esparza, Ruben M. Munoz, Jolene K. Diedrich, Nicole M. Sodir, Jasmine R. Mueller, Cory R. Fraser, Erkut Borazanci, David Propper, Daniel D. Von Hoff, Christopher Liddle, Ruth T. Yu, Annette R. Atkins, Haiyong Han, Andrew M. Lowy, Michael T. Barrett, Dannielle D. Engle, Gerard I. Evan, Gene W. Yeo, Michael Downes & Ronald M. Evans","doi":"10.1038\/s41467-023-40798-6","paper_title":"A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer","subhead":"Salk researchers identified new set of molecules that drive growth of human pancreatic cancer cell lines, potentially leading to new therapeutic targets","home_photo":"","listing_photo":"","legacy_boilerplate":[],"hide_boilerplate":[],"disable_date":false,"listing_excerpt":"","descriptive_blurb":"","has_journal_cover":false,"og_image_override":false},"_links":{"self":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disclosure\/42469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disclosure"}],"about":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/types\/disclosure"}],"version-history":[{"count":13,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disclosure\/42469\/revisions"}],"predecessor-version":[{"id":47872,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disclosure\/42469\/revisions\/47872"}],"wp:attachment":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/media?parent=42469"}],"wp:term":[{"taxonomy":"faculty","embeddable":true,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/faculty?post=42469"},{"taxonomy":"disease-research","embeddable":true,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disease-research?post=42469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}